Neera Clase - 01 Nov 2026 Form 3 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
05 Nov 2026, 16:39:58 UTC
Next SEC filing
05 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Sieckert, Attorney-in-Fact
Filing notes and source

Key filing fact

Neera Clase filed Form 3 for Tarsus Pharmaceuticals, Inc. (TARS) on 05 Nov 2026.

Key facts

  • This page summarizes Neera Clase's Form 3 filing for Tarsus Pharmaceuticals, Inc. (TARS).
  • 0 reported transactions and 10 derivative rows are listed below.
  • Accepted by SEC: 05 Nov 2026, 16:39.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002162845 Primary reporting owner

Clase Neera

Relationship
Chief Commercial Officer
Address
C/O TARSUS PHARMACEUTICALS, INC., 17700 LAGUNA CANYON ROAD, FLOOR 4, IRVINE
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Signature date
05 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
14,800
Date
01 Nov 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,000
Exercise price
$25.56
Footnotes
F1
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,701
Exercise price
$19.59
Footnotes
F2
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,909
Exercise price
$15.00
Footnotes
F3
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,119
Exercise price
$35.50
Footnotes
F4
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,126
Exercise price
$44.54
Footnotes
F5
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,007
Exercise price
$74.90
Footnotes
F6
TARS holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,864
Exercise price
$0.000000
Footnotes
F7
TARS holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,080
Exercise price
$0.000000
Footnotes
F8
TARS holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,014
Exercise price
$0.000000
Footnotes
F9
TARS holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,147
Exercise price
$0.000000
Footnotes
F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

Options granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). 25% of the option shares vested and became exercisable on August 16, 2022, and 1/48th of the option shares vested each month thereafter for a period of 3 years.

Footnote F2

Options granted under the Plan. 25% of the option shares vested and became exercisable on March 9, 2023, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F3

Options granted under the Plan. 25% of the option shares vested and became exercisable on March 8, 2024, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F4

Options granted under the Plan. 25% of the option shares vested and became exercisable on March 7, 2025, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F5

Options granted under the Plan. 25% of the option shares vested and became exercisable on March 5, 2026, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F6

Options granted under the Plan. 25% of the option shares will vest and become exercisable on March 5, 2027, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F7

Restricted Stock Units ("RSUs") granted under the Plan. The RSUs shall vest on March 15, 2027, subject to the Reporting Person's continuous service.

Footnote F8

RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15, 2027 and March 15, 2028, subject to the Reporting Person's continuous service.

Footnote F9

RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

Footnote F10

RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .